Replies to post #96 on Equity Field Notes from temporal sources

[DanWebzster]

RYTM is testing lead compound in 6 rare indications. Total addressable market in U.S. & EU = 15K patients

4/2/18 in-licensed appetite control from Takeda for $5mn upfront

12/31/17 had $148mn cash with a runway into H2/2019.